Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule

Anti-Cancer Drugs

Volumn 20, Issue 8, 2009, Pages 659-667

  Heravi, Mitra ^a   Rachid, Zakaria ^a   Goudarzi, Atta ^a   Schlisser, Ava ^a   Jean Claude, Bertrand J ^a   Radzioch, Danuta ^a   Muanza, Thierry M ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Apoptosis; Cell cycle; Clonogenic survival; Combi molecule; Comet assay; Epidermal growth factor receptor tyrosine kinase inhibitor; Ionizing radiation

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FD 105; GEFITINIB; MOLECULAR THERAPY AGENT; UNCLASSIFIED DRUG; ZRBA 1;

ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA ALKYLATION; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; FLOW CYTOMETRY; GENE TARGETING; HUMAN; HUMAN CELL; IONIZING RADIATION; MOLECULAR MECHANICS; MOLECULAR THERAPY; PRIORITY JOURNAL; PROTEIN BINDING; RADIATION ATTENUATION; RECEPTOR DOWN REGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MICROSCOPY, FLUORESCENCE; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIAZENES; TUMOR STEM CELL ASSAY; X-RAYS;

EID: 70349314784     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832cb8bc     Document Type: Article

References (28)

1. Belka C, Camphausen KA. Why radiation oncology? Radiat Oncol 2006; 1:1.
2. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006; 6:876-885.
3. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006; 16:2-9.
4. Matheson SL, Mcnamee JP, Jean-Claude BJ. Design of a chimeric 3-Methyl-1,2,3 triazene with mixed Receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ther 2001; 296:832-840.
5. Dubner D, Pérez MD, Michelin S, Bourguignon M, Moreau P, Carsella ED, Gisone P. Pharmacological inhibition of DNA repair enzymes differentially modulates telomerase activity and apoptosis in two human leukaemia cell lines. Int J Radiat Biol 2004; 8:593-605.
6. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005; 31:603-617.
7. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9:59-71.
8. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
9. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-225.
10. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004; 10:136-143.
11. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37:S9-S15.
12. Barker FG II, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 51: 410-418.
13. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003; 159:439-452.
14. Brahimi F, Rachid Z, Qiu Q, McNamee JP, Li YJ, Tari AM, et al. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int J Cancer 2004; 112:484-491.
15. Matheson SL, Brahimi F, Jean-Claude BJ. The combi-targetin G concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/ DNA targeting combi-triazene SMA41. Biochem Pharmacol 2004; 67:1131-1138.
16. Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by Combi-triazene BJ2000, a new probe for combi-targeting postulates. J Pharmacol Exp Ther 2002; 303:238-246.
17. Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, et al. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother Pharmacol 2003; 51:1-10.
18. Matheson SL, McNamee JP, Jean-Claude BJ. Differential responses of EGFR-/AGT-expressing cells to the combi-triazene SMA41. Cancer Chemother Pharmacol 2003; 51:11-20.
19. Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ. Mechanism of action of a novel combi-triazene engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol 2005; 70:511-519.
20. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
21. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006; 12:4738-4746.
22. Merayo N, Rachid Z, Qiu Q, Brahimi F, Jean-Claude BJ. The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anticancer Drugs 2006; 17:165-171.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
24. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008; 14:931-938.
25. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-Ribose) polymerase inhibitor E7016. Clin Cancer Res 2009; 15:607-612.
26. Olive PL, Banáth JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 2006; 1:23-29.
27. Alvarez D, Chou CJ, Latella L, Zeitlin SG, Ku S, Puri PL, et al. A two-hit mechanism for pre-mitotic arrest of cancer cell proliferation by a polyamide-alkylator conjugate. Cell Cycle 2006; 5:1537-1548.
28. Hall EJ. Radiobiology for radiologist. 5th ed. Philadephia: Lippincott Williams & Wilkins; 2000.